When did Entresto Receive FDA Approval?
Entresto (sacubitril/valsartan) was approved by the U.S. Food and Drug Administration (FDA) on July 7, 2015 [1]. This approval was for the treatment of symptomatic chronic heart failure with reduced ejection fraction in adult patients [1].
What is Entresto Used For?
Entresto is prescribed to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with symptomatic chronic heart failure and reduced ejection fraction [1]. It is a combination medication containing sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker [1].
How Does Entresto Work?
Sacubitril works by increasing the levels of natriuretic peptides in the body, which help to relax blood vessels, reduce sodium and water retention, and decrease the workload on the heart. Valsartan blocks the effects of angiotensin II, a hormone that constricts blood vessels and raises blood pressure [1]. By combining these two mechanisms, Entresto aims to improve heart function and reduce the strain on the cardiovascular system.
When Does Entresto Patent Protection Expire?
The patent landscape for Entresto is complex and involves multiple patents covering different aspects of the drug, including its composition, manufacturing, and uses. According to DrugPatentWatch.com, there are several patents associated with Entresto, with expiration dates extending into the future [2]. For example, some patents related to Entresto's use in heart failure are noted to expire in the late 2020s and early 2030s [2].
Can Generic Versions of Entresto Be Available?
The availability of generic versions of Entresto depends on the expiration of its associated patents and any periods of market exclusivity granted by regulatory agencies. As patent expirations approach, companies may seek approval for generic versions of the drug. However, challenges to patents or further patent filings can alter these timelines [2].
Who Manufactures Entresto?
Entresto is manufactured by Novartis [1].
---
1. U.S. Food and Drug Administration. (2015, July 7). FDA approves new heart failure medicine Entresto. https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/fda-approves-new-heart-failure-medicine-entresto
2. DrugPatentWatch.com. (n.d.). Entresto Patent Expirations. https://www.drugpatentwatch.com/